Journal article

Targeting Breast Cancer Complexity: Molecular Signalling, Microenvironment and Next-Generation Therapeutic Strategies

TLTanjima Tarique Laskar MAMonica Arora JMJiaul Ahmed Mazumder RBRupajit Bhattacharjee MHMd Ikbal Husain BDBandana Das PDPanchami Das PCParomita Dutta Choudhury JSJhankar Sharma SGSuhani Gogoi
Year2025
Volume43
Issue8
Pages464-506

Abstract

Breast cancer is a leading global health concern characterized by molecular heterogeneity and
complex pathogenesis, fueled by intricate signaling pathways that trigger its genesis,
progression and therapeutic resistance. This assessment delves into the elucidation of intricate
molecular pathways navigating oncogenic cascades, including hormone receptor signaling
driven by estrogen and progesterone, HER2-mediated cascades, PI3K/AKT/mTOR,
RAS/MAPK, Wnt/β-catenin, JAK/STAT and Notch signaling pathways, alongside their
influence on tumor behavior through interplay with metabolic reprogramming notably the
Warburg effect and epigenetic modifications, including DNA methylation and histone
alterations. The tumor microenvironment, comprising anti-inflammatory macrophages, tumor-
infiltrating lymphocytes, cancer-associated fibroblasts and the extracellular matrix, further
governs immune evasion, angiogenesis and metastasis. This review underscores advancements
in therapies targeting these pathways, including endocrine therapies (selective estrogen
receptor modulators, aromatase inhibitors, selective estrogen receptor degraders), immune
checkpoint inhibitors (pembrolizumab, atezolizumab), HER2-targeted agents (trastuzumab, T-
DXd), CDK4/6 inhibitors (palbociclib, ribociclib) and PARP inhibitors (olaparib, talazoparib).
It also emphasizes emerging cutting-edge strategies, such as antibody-drug conjugates,
PROTACs and RNA-based therapies (siRNAs, antisense oligonucleotides) to overcome drug
resistance and enhance personalized therapies. Despite significant advancements, challenges
such as tumor heterogeneity, pathway crosstalk, clonal evolution, immune suppression and
acquired resistance reinforce the need for biomarker-driven combination therapies. By
integrating multi-omics and AI-driven technologies into drug development, future treatment
prospects aim to achieve personalized, durable and sustained responses to improve patient
outcomes.

Cite this article